PR Newswire
LONDON, Feb. 17, 2026
LONDON, Feb. 17, 2026 /PRNewswire/ — The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and projected to reach US$3.7 billion by 2033, with a CAGR of 5.8% during the forecast period. Market expansion stems from increasing demand for regenerative therapies, advances in biopharmaceutical manufacturing, and growing investment in cell and gene therapies. Growth factors enable therapeutic innovation, tissue engineering protocols, and high-precision biologics production, making them indispensable in modern healthcare and life sciences. Recent improvements in recombinant production and protein engineering are also helping to streamline supply chains and enhance product efficacy.
https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
Surge in Regenerative Medicine and Oncology Research
Demand for regenerative medicine and oncology applications is a key growth driver for the market. Growth factors such as interleukins, platelet-derived, and vascular endothelial growth factors are central to wound healing, tissue repair, and targeted cancer therapies. The growing incidence of chronic diseases and global research funding boost adoption in clinical and research settings. Interleukins alone held a 21.2% share of the market by product in 2025, underlining their broad utility in immunotherapy, inflammation studies, and cell signaling research. Carrier and academic research facilities worldwide increasingly integrate growth factors into protocols for cell culture expansion, immunology studies, and precision medicine programs. As personalized therapies advance, demand for specialized, high-purity growth factors continues to rise. Manufacturing innovations, including recombinant technology and animal-free production techniques, are improving scalability and lowering barriers to adoption.
Get Free Sample Now: https://www.persistencemarketresearch.com/samples/4456
Key Highlights:
• The market is projected to reach US$3.7 billion by 2033, expanding at a CAGR of 5.8% driven by regenerative medicine and cell therapy adoption.
• Interleukins lead with 21.2% market share, supported by strong demand in oncology, immunotherapy, and autoimmune research.
• Colony-Stimulating Factors (CSFs) are the fastest-growing segment, fueled by rising applications in cancer supportive care and bone marrow recovery.
• Over 2,200 active cytokine-related clinical trials globally reinforce sustained research-driven demand.
• North America holds the largest revenue share, while Asia Pacific emerges as the fastest-growing region due to expanding biopharma manufacturing and R&D investment.
Technological Innovation and Enhanced Biomanufacturing Efficiency
Advancements in biotechnology are another significant driver of market growth. Improved methods for synthesizing high-activity growth factors and integration of quality-by-design (QbD) approaches enable better performance and consistency for clinical and commercial use. This trend is particularly strong in biopharmaceutical process development, where growth factors support ex vivo cell expansion, tissue engineering, and stem cell-based therapies. Market players are also focusing on GMP-grade production, ensuring safety, traceability, and compliance with regulatory standards, especially for therapeutic applications. As biologics manufacturing expands, bioprocessing facilities require reliable, high-quality growth factor inputs that meet stringent regulatory requirements, reinforcing the need for advanced solutions.
Key Highlight: Bio-Techne Launches Next Generation Cytokines & Growth Factors
• In 2025, Bio-Techne introduced its next generation line of cytokines and growth factors, expanding its portfolio of high-quality recombinant proteins. This new series combines the established reputation of R&D Systems proteins with Bio-Techne’s modernized methods of protein expression and purification, designed to improve supply reliability and overall product performance for research and therapeutic workflows.
• The next generation proteins offer increased manufacturing supply and enhanced supply-chain reliability, helping researchers avoid disruptions during all stages of their work. These proteins are also positioned to provide time and cost savings through larger lot sizes that reduce the need for bridging studies when transitioning between product batches.
• In terms of quality and performance, the new proteins maintain equivalent bioactivity to legacy products, while delivering high lot-to-lot consistency, high purity, and industry-leading low endotoxin levels (>95 % purity, low endotoxin).
• The launch covers numerous recombinant proteins, including key cytokines, growth factors, and cell culture reagents, such as IL-2, IL-4, IL-7, IL-15, SCF, VEGF, FGF basic/FGF2, TGF-β1, TGF-β3, and more, presented alongside legacy versions for direct comparison.
The initiative supports a streamlined transition from research-use-only (RUO) applications into clinical-grade (GMP) proteins, giving scientists flexibility when progressing projects from basic research to therapeutic development.
Request For Customization:
https://www.persistencemarketresearch.com/request-customization/4456
By Product, Interleukins Dominate While Colony-Stimulating Factors Show Fastest Growth
Interleukins hold 21.2% of the global growth factors market share, making them the leading product segment due to their central role in immune regulation, inflammation control, and cell proliferation. Among them, Interleukin-2 (IL-2) accounts for nearly 45% of the recombinant human interleukin segment, reflecting strong clinical adoption in cancer immunotherapy and immune modulation therapies. The segment continues to benefit from more than 2,200 active cytokine-related clinical trials worldwide, reinforcing sustained research demand. Meanwhile, recombinant growth factors used in cell and gene therapy applications represent the fastest-growing subsegment, driven by expanding CAR-T and T-cell activation pipelines. A notable 2025 development includes biotech firms scaling GMP-grade recombinant interleukin production to support next-generation immunotherapies, strengthening the segment’s commercial outlook.
Regional Insights: Asia Pacific Follows North America Growth Factors market
North America holds the largest share of the growth factors market, accounting for approximately 39.8% of global value, supported by robust R&D infrastructure, high healthcare spending, and strong biotech sectors. Major pharmaceutical and life sciences hubs in the U.S. and Canada drive adoption of advanced biologics and regenerative therapies.
The Asia-Pacific region is the fastest-growing market, fueled by expanding biopharmaceutical manufacturing capabilities, increasing government support for biotechnology initiatives, and rising healthcare expenditure. Countries such as China, India, and Japan are scaling up research facilities and production capacity to meet global demand.
Europe demonstrates steady demand, backed by strong research networks and supportive regulatory frameworks. Latin America and the Middle East show growth potential through investments in healthcare infrastructure and clinical research activities. Trade trends indicate strategic shifts toward localized production in growth markets to reduce costs and enhance supply chain resilience.
Key Players and Business Strategies
Leading players in the growth factors market include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Lonza Group, and F. Hoffmann-La Roche.
– Thermo Fisher Scientific is expanding R&D and manufacturing capabilities to reinforce growth factor innovation and support global supply.
– Merck KGaA invests in recombinant protein production and quality-driven bioprocessing solutions.
– Bio-Rad Laboratories focuses on portfolio diversification and partnerships to strengthen market reach.
– Lonza Group targets scalable production solutions for cell and gene therapy applications.
– F. Hoffmann-La Roche leverages its clinical pipeline to integrate specialized growth factors in therapeutic research.
Strategies emphasize collaboration, technological innovation, enhanced GMP compliance, and alignment with emerging therapeutic trends to meet diverse industry needs.
Key Players in the Growth Factor Market
• Thermo Fisher Scientific Inc.
• PeproTech Inc.
• R&D Systems Inc. (Bio-Techne Corporation)
• Miltenyi Biotec GmbH
• Corning Incorporated
• CellGenix GmbH
• Lonza Group AG
• Sino Biological Inc.
• Abcam plc
• STEMCELL Technologies Inc.
• Sigma-Aldrich Corporation (Merck KGaA, Darmstadt, Germany)
• Novoprotein Scientific Inc.
• Tonbo Biosciences Inc.
• Tocris Bioscience (Bio-Techne Corporation)
• Koma Biotech Co. Ltd.
Buy Now: https://www.persistencemarketresearch.com/checkout/4456
Market Segmentation
By Product
• Transforming Growth Factors (TGF)
o Activin
o Bone Morphogenetic Proteins (BMPs)
o TGF-beta Proteins
• Epidermal Growth Factors (EGFs)
• Platelet-derived Growth Factors (PDGFs)
• Fibroblast Growth Factors (FGFs)
• Insulin-like Growth Factors (IGFs)
• Vascular Endothelial Growth Factors (VEGFs)
• Hepatocyte Growth Factors (HGFs)
• Tumor Necrosis Factors (TNFs)
• Interleukins
• Others
By Grade
• GMP Grade
• NON-GMP Grade
By Application
• Oncology
• Hematology
• Wound Healing
• Dermatology
• Cardiovascular Disease and Diabetes
• Cell Therapy and EX-vivo Manufacturing
• Others
By Expression Host System
• Animal-derived
• Recombinant
By Mode of Action
• Angiogenic
• Anti-apoptotic
• Mitogenic
By Species Origin
• Human
• Pig
• Mouse
• Rat
• Others
By End User
• Pharmaceutical and Biotechnology Companies
• Research Centers and Academic Institutes
• Contract Research Organizations
By Region
• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa
Related
Biotechnology Reports
:
Therapeutic Enzymes Market by Product Type (Asparaginase, Streptokinase, Lipase, Collagenase, Lysozyme, Others), Application (Leukemia, Antiviral Therapy, Stomach Disorders, Skin Ulcers, Others), End-user (Hospitals, Clinics, Research Laboratories, Others), and Regional Analysis for 2026-2033
Miscarriage Testing Market by Technology (Chromosomal Microarray Analysis (CMA), Next-Generation Sequencing (NGS), Conventional Karyotyping, Fluorescence in Situ Hybridization), Application (Recurrent Pregnancy Loss (RPL), First-Time Sporadic, Stillbirth Analysis, Threatened Miscarriage Evaluation), End-User (Hospitals, Fertility Clinics, Research and Academic Institutions), and Regional Analysis for 2026-2033
Microbiome Manufacturing Market by Formulation (Solid, Liquid, Others), Primary Packaging (Blister Packs, Glass Bottles, Plastic Bottles, Pouches, Vials), Company Size (Small, Mid-sized, Large & Very Large), and Regional Analysis for 2026-2033
Buffer Preparation Market by System Type (Automated, Single Use, Manual & Semi Automated, Continuous), Formulation Type (Liquid Buffers, Powder (Dry) Buffers, Concentrated Buffers, Pre prepared Buffers), End-User (Biopharmaceutical & Biotechnology Companies, CDMOs, Academic & Research Institutions, Clinical Laboratories & Diagnostic Centers, Hospitals & Healthcare Providers), and Regional Analysis for 2026-2033
Whole Genome Sequencing Market by Product (Instruments, Consumables, Services), by Sequencing Type (Large Whole Genome Sequencing, Small Whole Genome Sequencing), by End User (Pre-sequencing, Sequencing, Data Analysis), by Regional Analysis, from 2026 to 2033
Metabolomics biomarker market by Indication (Cardiovascular, Others), Application (Drug Designing, Others), End-user (Hospitals, Research Laboratories, Cancer Research Centers, Diagnostic Laboratories), and Regional Analysis for 2026 – 2033
High-Resolution Melting Analysis Market by Product (Reagents, Instruments, Software & Services), Application (Detection of Acquired Mutations/Mutation Scanning/SNP Typing, Microbial Species Identification, Zygosity Testing, Epigenetics/Methylation Profiling and Drug-Resistant), End User (Academic Research, Clinical Diagnostics), and Regional Analysis from 2026 to 2033
Preimplantation Genetic Testing Market by Product (Kits, Reagents and Consumables), by Technology (Next-Generation Sequencing, Fluorescence In Situ Hybridization, Polymerase Chain Reaction, Single-Nucleotide Polymorphism, and Comparative Genomic Hybridization), Application, by Distribution Channel, Regional Analysis, 2026-2033
High Throughput Process Development Market by Tools & Systems (Manual Tools, Automated Tools, Analytical Tools, High Throughput Integrated Bioreactor Systems), by Application (Bioprocess Development, Drug Discovery, Vaccine Development, Quality Control), by Process Stage (Upstream Process Development, Downstream Process Development), by End User (Biopharmaceutical & Biotechnology Companies, Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes), by Regional Analysis, 2026-2033.
Muscle Stimulation Devices Market by Product Type (Neuromuscular Electric Stimulator (NMES), Transcutaneous Electric Nerve Stimulator (TENS), Interferential (IF), Burst Mode Alternating Current), by Application (Pain Management, Neurological & Movement Disorder Management, Musculoskeletal Disorder Management), End-user (Hospitals, Physiotherapy Clinics, Sports Clinics, Home Care Settings), by Regional Analysis 2026 – 2033
About Persistence Market Research:
At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviors, and competitive intelligence! For over a decade, we’ve been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.
Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today’s competitive environment.
ContactRitika KhandelwalPersistence Market ResearchSecond Floor, 150 Fleet Street, London, EC4A 2DQ+44 203-837-5656United KingdomUSA Phone – +1 646-878-6329Email: [email protected]
Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/growth-factors-market-to-reach-us-3-7-bn-by-2033–expands-amid-rising-regenerative-medicine-and-biopharmaceutical-innovation–persistence-market-research-302689712.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…